To investigate the impact of fibroblast-derived microenvironmental factors on KRAS-driven effects, we profiled the total proteome of two distinct mutKRAS CRC cell lines (HCT116 and LS174T) upon KRAS silencing followed by treatment with CM from rhTGFβ1-activated fibroblasts (siKRAS_FibCM). This evidence concerns the gene KRAS and colorectal carcinoma.